Patients who are able to tolerate flexible bronchoscopy Patients who are deemed unable to safely undergo or tolerate flexible bronchoscopy were unable to tolerate the prior first-line regimen There is no upper age limit but the patients must be able to medically tolerate the regimen Willing to undergo and able to tolerate frequent MRI or CT assessments during the study Patient is unable to tolerate MRI (foreign body; i.e. pacemaker or other implanted device; claustrophobia; inability to tolerate rectal coil, etc) Patients who cannot tolerate pneumocystis jirovecii pneumonia (PJP) prophylaxis (i.e., known Bactrim and pentamidine allergies) Patients must be able to tolerate apheresis procedure, including placement of temporary apheresis line if required Tolerate a g ascorbate infusion (screening dose) Patients that cannot tolerate MRI Subjects must be able to tolerate apheresis procedure, including placement of temporary apheresis line if required Patients unable to tolerate transrectal ultrasound. Subjects must be able to tolerate apheresis procedure, including placement of temporary apheresis line if required Able to tolerate prone body positioning during radiation therapy Patients who have had prior everolimus but were not able to tolerate a mg daily dose Co-morbidities precluding patient's ability to tolerate BMT Patients with KPS < and/or unable to tolerate potentially longer treatment times Unable to tolerate anti-viral and anti-Pneumocystis jirovecii prophylaxis while on pre-phase and remission induction therapy Tolerate one test dose ( g) of ascorbate Patient is able to tolerate apheresis procedure including placement of temporary apheresis catheter if necessary or has prior apheresis product of x ^ mononuclear (MNC) cells available for use Patient must be able to tolerate lying in the prone position with arms extended forward Must be able to tolerate MRI scan with contrast COHORT II: Patient must be able to tolerate lying in the prone position with arms extended forward COHORT II: Must be able to tolerate MRI scan with contrast Able to tolerate pre / post - procedure steroid treatment Individuals who are not able or willing to tolerate the required prolonged stationary position during treatment (can be up to hrs of total table time.) Patients who cannot tolerate intravesical dosing or intravesical surgical manipulation Patient unable to tolerate lymphodepletion, low-dose IL- and/or IMA product Tolerate one test dose (g) of ascorbate Ineligible for curative loco regional treatment and have progressed on or did not tolerate approved treatments of Erivedge (vismodegib, also known as GDC ) and Odomzo (sonidegib, also known as erismodegib or LDE) and have progressed on did not tolerate or are unwilling to try other investigational agents Willing and able to tolerate brain MRI's with contrast Patients that cannot tolerate MRI Subject is not an appropriate candidate for, or unable to tolerate, flexible bronchoscopy procedures Ability to tolerate intensive therapy with vosaroxin mg/m^ and standard dose of cytarabine as per investigator discretion Tolerate a g ascorbate infusion (screening dose) Able to tolerate intraperitoneal (IP) port placement and IP treatment administration in the opinion of the enrolling investigator Patient is unable to tolerate placement of a stereotactic head frame Patients who cannot tolerate intravesical dosing or intravesical surgical manipulation Unable to tolerate thromboembolic prophylaxis while on the study SUB-PROTOCOL AIM A: Previously treated patients who have failed, unable to tolerate, or refused other available active therapies Tolerate one test dose ( g) of ascorbate Able to tolerate high-dose cyclophosphamide, fludarabine and high-dose IL- Able to tolerate high-dose cyclophosphamide, fludarabine, and high-dose IL- Individuals who are not able or willing to tolerate the required prolonged stationary supine position during treatment (approximately hrs.) Patients must be able to tolerate MRI scans Patients who have previously been unable to tolerate ceritinib, in the opinion of the investigator. Exceptions to this exclusion include nausea, vomiting and diarrhea in patients taking ceritinib under fasted conditions. Ability to tolerate FCR based therapy Tolerate one test dose ( g) of ascorbate Patients that cannot tolerate being scanned for an additional minutes with arms above their head will be excluded. Patients with demonstrated allergy to TMZ or who are otherwise unable to tolerate TMZ for any reason will be excluded and replaced if needed; patients who are found after enrollment to be unable to tolerate TMZ will not be a candidate for the vaccine despite being previously enrolled and will be removed from the study and replaced Patient is able to tolerate being in the MRI scanner for the duration of the study Individuals who are not able or willing to tolerate the required prolonged stationary position during treatment (can be up to hours [hrs] of total table time) Patients that were unable to tolerate at least cycle of an alkylating agent plus corticosteroid (e.g. melphalan + dexamethasone) or alternative prior regimen because of severe adverse events (e.g. hypersensitivity reaction) may be considered after discussion with the study PI/Medical Monitor. Patients must have measurable contrast-enhancing progressive or recurrent glioblastoma by MRI within days of starting treatment; patient must be able to tolerate MRIs Must be able to tolerate MRI scan procedure Individuals who are not able or willing to tolerate the required prolonged stationary position during treatment (approximately hrs.) Subject is able to tolerate endoscopy Previously unable to tolerate either supplement due to taste or gastrointestinal (GI) side effects. Are able to tolerate surgery (i.e., segmentectomy, lobectomy or bilobectomy) as indicated by standard clinical pre-op evaluation, including pulmonary function tests and cardiac evaluation (if indicated) Able to tolerate high-flow oxygen/air Able to tolerate enteral drug administration Ability to tolerate thin liquids by mouth at the time of admission Able to tolerate prone position and breath hold during CT simulation Patients must be able to tolerate MRI/CT scans Patients unable to tolerate discontinued use of anti-coagulants prior to and during the ablation procedure. Tolerate sitting in a rocking or nonrocking chair Patients must be able to tolerate digital breast tomosynthesis and full-field digital mammographic imaging required by protocol EXCLUSION - PATIENT: Unable to tolerate exam (i.e., secondary to untreatable claustrophobia, positioning constraints/unable to lie prone) Individuals who are not able or willing to tolerate the required prolonged stationary supine position during treatment (approximately hrs. sonication time) Subjects who could not tolerate a PI, IMiDs, or a CD-directed cytolytic antibody are eligible to enroll in the study. Patient is incontinent of urine or stool (which would make them unable to tolerate lying still for minutes) Patients unable to tolerate a SPECT/CT mTc-SC scan Unable to tolerate MRI without anesthesia Patients able to tolerate PET/MRI scans Patients who are unable to tolerate surgery Patient not able to tolerate MRI scan due to claustrophobia or severe pain or allergic reaction to contrast Unable to tolerate up to min of PET imaging per imaging session Deemed unable to safely undergo or tolerate flexible bronchoscopy as per institutional guidelines Able to tolerate MRI Patients who cannot tolerate the vaginal ultrasound procedure Able to tolerate supine position Able to tolerate an MRI examination Unable to tolerate min of PET imaging per imaging session Patients unable to tolerate a SPECT/CT mTc-MAA and mTc-DTPA scan Patients who cannot tolerate imaging up to minutes of total imaging (breaks of several minutes between imaging will be available) Able to eat a full range of solid food and liquids and tolerate seeds/nuts Must be able to tolerate PET/CT (i.e. not claustrophobic and able to remain supine) Patient must be able to tolerate a major surgical procedure based on clinical evaluation, status of their cancer, and any other underlying medical problems Patients who are able to tolerate flexible bronchoscopy.